Advert - Novartis – Case AUTH/3635/4/22

For use of a claim in an Entresto (sacubitril/valsartan) podcast, in the absence of any qualification, which downplayed the importance of renal function and was thereby misleading and incapable of substantiation Novartis was ruled in breach of the following clauses of the 2021 Code:

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1        - Failing to maintain high standards

Clause 6.1        - Providing misleading information

Clause 6.2       - Making a claim incapable of substantiation

Clause 14.4      - Implying that a medicine has some special merit, quality or property